Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer

Leena Kankaanranta, Tiina Seppälä, Hanna Koivunoro, Kauko Saarilahti, Timo Atula, Juhani Collan, Eero Salli, Mika Kortesniemi, Jouni Uusi-Simola, Antti Mäkitie, Marko Seppänen, Heikki Minn, Petri Kotiluoto, Iiro Auterinen, Sauli Savolainen, Mauri Kouri, Heikki Joensuu (Corresponding Author)

Research output: Contribution to journalArticleScientificpeer-review

100 Citations (Scopus)

Abstract

Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33%) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.

Original languageEnglish
Pages (from-to)475-482
JournalInternational Journal of Radiation Oncology Biology Physics
Volume69
Issue number2
DOIs
Publication statusPublished - 1 Oct 2007
MoE publication typeA1 Journal article-refereed

Fingerprint

Boron Neutron Capture Therapy
Head and Neck Neoplasms
therapy
boron
cancer
neutrons
tumors
Neck
Therapeutics
Head
Carcinoma
Xerostomia
Neoplasms
Mucositis
Boron
National Cancer Institute (U.S.)
Deglutition Disorders
irradiation
Fructose
pain

Keywords

  • Boron neutron capture therapy
  • Boronophenylalanine
  • Head and neck cancer
  • Positron emission tomography
  • Radiotherapy

Cite this

Kankaanranta, L., Seppälä, T., Koivunoro, H., Saarilahti, K., Atula, T., Collan, J., ... Joensuu, H. (2007). Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 69(2), 475-482. https://doi.org/10.1016/j.ijrobp.2007.03.039
Kankaanranta, Leena ; Seppälä, Tiina ; Koivunoro, Hanna ; Saarilahti, Kauko ; Atula, Timo ; Collan, Juhani ; Salli, Eero ; Kortesniemi, Mika ; Uusi-Simola, Jouni ; Mäkitie, Antti ; Seppänen, Marko ; Minn, Heikki ; Kotiluoto, Petri ; Auterinen, Iiro ; Savolainen, Sauli ; Kouri, Mauri ; Joensuu, Heikki. / Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. In: International Journal of Radiation Oncology Biology Physics. 2007 ; Vol. 69, No. 2. pp. 475-482.
@article{924846a0d2a04304b86c0576698f512e,
title = "Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer",
abstract = "Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83{\%}) patients responded to BNCT, and 2 (17{\%}) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33{\%}) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.",
keywords = "Boron neutron capture therapy, Boronophenylalanine, Head and neck cancer, Positron emission tomography, Radiotherapy",
author = "Leena Kankaanranta and Tiina Sepp{\"a}l{\"a} and Hanna Koivunoro and Kauko Saarilahti and Timo Atula and Juhani Collan and Eero Salli and Mika Kortesniemi and Jouni Uusi-Simola and Antti M{\"a}kitie and Marko Sepp{\"a}nen and Heikki Minn and Petri Kotiluoto and Iiro Auterinen and Sauli Savolainen and Mauri Kouri and Heikki Joensuu",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2007.03.039",
language = "English",
volume = "69",
pages = "475--482",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier",
number = "2",

}

Kankaanranta, L, Seppälä, T, Koivunoro, H, Saarilahti, K, Atula, T, Collan, J, Salli, E, Kortesniemi, M, Uusi-Simola, J, Mäkitie, A, Seppänen, M, Minn, H, Kotiluoto, P, Auterinen, I, Savolainen, S, Kouri, M & Joensuu, H 2007, 'Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer', International Journal of Radiation Oncology Biology Physics, vol. 69, no. 2, pp. 475-482. https://doi.org/10.1016/j.ijrobp.2007.03.039

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. / Kankaanranta, Leena; Seppälä, Tiina; Koivunoro, Hanna; Saarilahti, Kauko; Atula, Timo; Collan, Juhani; Salli, Eero; Kortesniemi, Mika; Uusi-Simola, Jouni; Mäkitie, Antti; Seppänen, Marko; Minn, Heikki; Kotiluoto, Petri; Auterinen, Iiro; Savolainen, Sauli; Kouri, Mauri; Joensuu, Heikki (Corresponding Author).

In: International Journal of Radiation Oncology Biology Physics, Vol. 69, No. 2, 01.10.2007, p. 475-482.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer

AU - Kankaanranta, Leena

AU - Seppälä, Tiina

AU - Koivunoro, Hanna

AU - Saarilahti, Kauko

AU - Atula, Timo

AU - Collan, Juhani

AU - Salli, Eero

AU - Kortesniemi, Mika

AU - Uusi-Simola, Jouni

AU - Mäkitie, Antti

AU - Seppänen, Marko

AU - Minn, Heikki

AU - Kotiluoto, Petri

AU - Auterinen, Iiro

AU - Savolainen, Sauli

AU - Kouri, Mauri

AU - Joensuu, Heikki

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33%) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.

AB - Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33%) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.

KW - Boron neutron capture therapy

KW - Boronophenylalanine

KW - Head and neck cancer

KW - Positron emission tomography

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=34548494642&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.03.039

DO - 10.1016/j.ijrobp.2007.03.039

M3 - Article

VL - 69

SP - 475

EP - 482

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -